To view this email as a web page, click here

   Home

Subscribe

Advertise

 

 

 

 

March 26, 2020___

Today's Rundown

Featured Story

COVID-19 prompts Pfizer to stop enrollment in most studies

Pfizer has paused enrollment in many new and ongoing clinical trials in response to the COVID-19 pandemic, Reuters reports. The action sees Pfizer join Bristol Myers Squibb and Eli Lilly on the list of Big Pharma companies to revise their R&D plans in light of the novel SARS-CoV-2 coronavirus.

Top Stories

Ipsen scraps pivotal trial as partial clinical hold drags on

Ipsen has terminated a pivotal trial of its troubled rare disease drug palovarotene in response to the ongoing clinical hold. The action likely deprives Ipsen of a shot at generating data to bring a drug it bought in a $1.3 billion (€1.2 billion) deal to market in a blockbuster indication.

Regenacy Pharma snags $30M for diabetic neuropathy treatment

Regenacy Pharmaceuticals scored $30 million to push a program for nerve damage stemming from diabetes into phase 2. Treatments for the condition, called diabetic peripheral neuropathy, tend to focus on managing pain, but Regenacy’s approach aims to reverse the nerve damage that causes that pain.

Cancer biotech Viracta nabs Nordic Nanovector exec as CMO

Lisa Rojkjaer, M.D., has been named Viracta’s new chief medical officer as Nordic Nanovector adds interim replacement.

Roche forges antibiotics pact as it sees beyond COVID-19 threats to public health

Swiss major Roche, already ramping up tests for the COVID-19 pandemic, isn’t taking its eye off of the infectious disease ball.

ReCode Therapeutics nets $80M to push RNA treatment for cystic fibrosis

Over the years, more and more patients with cystic fibrosis have benefited from new drugs such as Vertex’s Trikafta. But there is still a subset of patients with certain mutations for whom those drugs don’t work. Enter ReCode Therapeutics, which raised $80 million to advance a treatment for cystic fibrosis driven by what’re called nonsense mutations.

PRA Health Sciences unveils COVID-19 monitoring app to track symptoms

Contract research organization PRA Health has launched a new mobile app aimed at tracking patients’ physical and psychological symptoms from COVID-19.

Some states report incomplete COVID-19 results, blurring the full picture

Several states are reporting only positive COVID-19 test results from private labs, a practice that paints a misleading picture of how fast the disease is spreading.

Enrollment Showcase

What's the value of an MBA to healthcare and the life sciences?

Prepare to step up in your career, build the expertise you need to reshape your organization, and explore opportunities worldwide.

Resources

[Guide] Pandemic Survival Guide --- IT Solutions for Business Continuity

To survive in these challenging conditions, companies need to promptly address business continuity issues - especially the remote delivery of data and voice solutions. See how Outer Edge can help.

[Whitepaper] Ensuring the Greatest Return From Your Poorly Soluble Molecule

Poorly soluble molecules hindering your workflow?

[On Demand] Tufts-eClinical Solutions Data & Analytics Survey Results

Key findings from the 2019 Life Sciences Data & Analytics Survey conducted by the Tufts Center for the Study of Drug Development will be unveiled during this live webinar led by industry expert and study lead, Ken Getz, Director of Sponsored Programs and Associate Professor.

[eBook] Expecting the Unexpected: Strategies for Efficient Clinical Supply Management and Forecasting

Learn how to drive excellence within the forecasting process and utilize forecasting throughout the clinical study to better plan clinical supply budgets and project timelines. Explore how to identify potential supply-related issues before they can negatively impact your study.

[Fact Sheet] Forecasting to Optimize Clinical Trial Supply Management

Whether a study is simple or highly complex, forecasting and simulation reports serve as data driven communication tools to help minimize risks and keep the study on track. Learn more about forecasting solutions for informed decision making and supporting contingency planning for clinical study.

[Case Study] Establishing Parameters for Success

Learn about a real-world example of how clinical supply management expertise was applied to overcome inventory challenges for a complex, global study.

[Whitepaper] Why BioPharma Co’s Leverage the Cloud to Gain Competitive Advantage

See why innovative BioPharma’s are partnering with Cloud Service Provider’s to design, manage and implement cloud strategies to smooth the path to FDA approval and enhance their competitive prowess. 

[Whitepaper] Create A More Compelling Program Development Dossier With Metabolomics

Metabolomics can help you streamline your drug development process by providing the framework to make a stronger, more confident, and more valuable case for a molecule in a shorter timeframe.

[eBook] 9 Ways to Enhance Healthcare Customer Experiences

Download this e-book to learn 9 ways to enhance the customer experience within healthcare marketing.

[Whitepaper] The ROI of Document Delivery

3 ways you may be overspending on scientific literature access, and how to fix them.

[Whitepaper] Manufacturing Cytotoxic and Non-Cytotoxic

When different drug products are produced in shared facilities, potential for cross-contamination needs to be addressed.  Outsourcing to a CMO with experience in multiproduct facilities can be an option.

[Whitepaper] Measure the Right Things at the Right Time: Using A Metric Maturity Model to Optimize Performance Measurement

Ineffective measurement could mean wasting both time and money. This whitepaper showcases a custom-built Metric Maturity Model that helps illustrate and define the process for measuring the right things the right way.

[Whitepaper] Navigating Today’s Healthcare Transformation: The Evolution of Payers

Read about the innovative ways payers are making smart moves in the healthcare game.

[Executive Summary] Strategies for Flexible Manufacturing

This whitepaper discusses the benefits of end-to-end solutions and share case studies on how flexible manufacturing strategies can accommodate the changing landscape of pharmaceutical products and help bring a drug to market.

[Presentation] Flexible Manufacturing Strategies

Get expert insights on strategies to implement flexible manufacturing and different technologies that are easily scalable and reproducible.

[Executive Summary] Overcoming Manufacturing Challenges for Accelerated Drug Development

Regardless of the assigned FDA expedited approval designation and approach, the key action items should be: the assurance of a detail-oriented plan and the adaption of a “forward-thinking” approach that will assist in any future challenges and opportunities for growth of each project.

Events